Schusdziarra Volker, Zimmermann Jens P, Schick Rafael R
Department of Nutritional Medicine, Else-Kröner-Fresenius Center of Nutritional Medicine, Technical University of Munich, Munich, Germany.
Obes Res. 2004 Apr;12(4):627-32. doi: 10.1038/oby.2004.72.
Central feeding regulation involves both anorectic and orexigenic pathways. This study examined whether targeting both systems could enhance feeding inhibition induced by anorectic neuropeptides.
Experiments were carried out in 24-hour fasted rats. Intracerebroventricular (ICV) injections were accomplished through stereotaxically implanted cannulae aimed at the lateral cerebral ventricle. Food intake of standard rat chow pellets was subsequently recorded for 2 hours.
Blockade of orexigenic central opioids and neuropeptide Y (NPY) by ICV naloxone (25 microg) or the NPY receptor antagonist [D-Trp32]NPY (NPY-Ant; 10 micro g) powerfully augmented the feeding suppression induced by ICV glucagon-like peptide 1 (7-36)-amide (GLP-1; 10 microg) or xenin-25 (xenin; 15 microg) in 24-hour fasted rats. Most importantly, in combination with naloxone or NPY-Ant, even a low and ineffective dose of GLP-1 (5 microg) caused a 40% reduction of food intake, which was augmented further when both antagonists were given in combination with GLP-1. The combination of GLP-1 (5 microg) and xenin (10 microg) at individually ineffective doses caused a 46% reduction of food intake, which was abolished at a 10-fold lower dose. This ineffective dose, however, reduced food intake by 72% when administered in combination with naloxone and NPY-Ant.
Targeting up to four pathways of feeding regulation in the central nervous system by blockade of endogenous feeding stimuli and simultaneous administration of anorectic neuropeptides potentiated reduction of food intake. This raises a promising perspective for treatment of obesity.
中枢性进食调节涉及食欲抑制和食欲增强两条途径。本研究旨在探讨同时作用于这两个系统是否能增强食欲抑制性神经肽所诱导的进食抑制作用。
实验选用禁食24小时的大鼠。通过立体定位植入的套管向侧脑室进行脑室内(ICV)注射。随后记录2小时内标准大鼠饲料颗粒的摄入量。
脑室内注射纳洛酮(25微克)或神经肽Y受体拮抗剂[D-Trp32]神经肽Y(NPY-Ant;10微克)阻断内源性食欲增强的中枢阿片类物质和神经肽Y(NPY),可显著增强脑室内注射胰高血糖素样肽1(7-36)酰胺(GLP-1;10微克)或25肽胃泌素(xenin;15微克)对禁食24小时大鼠进食的抑制作用。最重要的是,与纳洛酮或NPY-Ant联合使用时,即使是低剂量且无效的GLP-1(5微克)也能使食物摄入量减少40%,当两种拮抗剂与GLP-1联合使用时,食物摄入量进一步减少。单独使用无效剂量的GLP-1(5微克)和xenin(10微克)联合使用可使食物摄入量减少46%,而剂量降低10倍时该作用消失。然而,当该无效剂量与纳洛酮和NPY-Ant联合使用时,食物摄入量减少了72%。
通过阻断内源性进食刺激并同时给予食欲抑制性神经肽,靶向中枢神经系统中多达四条进食调节途径可增强食物摄入量的减少。这为肥胖症的治疗带来了有前景的方向。